The motivation of this study was to determine whether dapagliflozin could improve NASH db/db mice, which are leptin receptor deficient and have obesity, hyperglycemia, hyperinsulinemia, insulin resistance, and fatty liver, widely used as an animal model of NAFLD (Santhekadur et al., 2018). Here, LEPR is linked to metabolic dysfunction-associated steatohepatitis.